NCT03331250View on ClinicalTrials.gov

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 18, 2018

Primary Completion Date

July 21, 2023

Study Completion Date

September 1, 2025

Conditions
AngiosarcomaEpithelioid Hemangioendothelioma
Interventions
DRUG

Eribulin

It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER